AD-2071

AD-2071 is an oral fixed-dose combination of **ezetimibe** and **rosuvastatin** developed in the Addpharma/Yuhan cardiovascular program. Ezetimibe inhibits intestinal cholesterol absorption through Niemann-Pick C1-like protein 1, while rosuvastatin is a selective competitive HMG-CoA reductase inhibitor that suppresses hepatic cholesterol synthesis and increases LDL receptor-mediated clearance of circulating LDL cholesterol. AD-2071 was evaluated as a 10 mg/20 mg tablet in a Phase 1 pharmacokinetic interaction study and was subsequently used in a completed Phase 3 study in patients with primary hypercholesterolemia and essential hypertension receiving concomitant antihypertensive treatment. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03632668))

Brand names

Rosuvamibe

Other names

ezetimibe + rosuvastatinezetimibe/rosuvastatinrosuvastatin + ezetimiberosuvastatin/ezetimibe